A selloff in Johnson & Johnson stock this month over potential legal damages from the alleged health risks of baby powder looks overdone, but the stock was expensive to start with, Jack Hough writes in this week’s edition of Barron’s. There are more deeply discounted health-care stocks for investors to consider, the report adds.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.